All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Aegis Life Inc. and its parent company Entos Pharmaceuticals Inc. (Entos) have entered into a grant agreement with the Bill & Melinda Gates Foundation in the area of infectious disease.
Amplo Biotechnology Inc. has been awarded a fast track phase I/II Small Business Technology Transfer (STTR) grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) to fund further development of AMP-201, an AAV-ColQ gene therapy designed to address congenital myasthenic syndrome caused by collagen Q (ColQ) deficiency.
Senisca Ltd. has been awarded a £571,350 (US$712,000) grant from Innovate UK toward the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF).
Vesigen Therapeutics Inc. has been awarded a grant by the Friedreich’s Ataxia Research Alliance (FARA) to develop a targeted genome editing therapeutic strategy for Friedreich’s ataxia.
Olatec Therapeutics LLC has been awarded a research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to evaluate its lead molecule, dapansutrile (OLT-1177), in preclinical Parkinson’s disease progression models.
Praetego Inc. has been granted a US$300,000 phase I Small Business Technology Transfer Research (STTR) award by the National Eye Institute (NEI) to advance the company's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.
RSS
